Blood-brain  ||| S:0 E:12 ||| JJ
barrier  ||| S:12 E:20 ||| NN
dysfunction-induced  ||| S:20 E:40 ||| JJ
inflammatory  ||| S:40 E:53 ||| JJ
signaling  ||| S:53 E:63 ||| NN
in  ||| S:63 E:66 ||| IN
brain  ||| S:66 E:72 ||| NN
pathology  ||| S:72 E:82 ||| NNS
and  ||| S:82 E:86 ||| CC
epileptogenesis  ||| S:86 E:102 ||| VBG
The  ||| S:102 E:106 ||| DT
protection  ||| S:106 E:117 ||| NN
of  ||| S:117 E:120 ||| IN
the  ||| S:120 E:124 ||| DT
brain  ||| S:124 E:130 ||| NN
from  ||| S:130 E:135 ||| IN
blood-borne  ||| S:135 E:147 ||| JJ
toxins ||| S:147 E:153 ||| NN
,  ||| S:153 E:155 ||| ,
proteins ||| S:155 E:163 ||| NNS
,  ||| S:163 E:165 ||| ,
and  ||| S:165 E:169 ||| CC
cells  ||| S:169 E:175 ||| NNS
is  ||| S:175 E:178 ||| VBZ
critical  ||| S:178 E:187 ||| JJ
to  ||| S:187 E:190 ||| TO
the  ||| S:190 E:194 ||| DT
brain ||| S:194 E:199 ||| NN
's  ||| S:199 E:202 ||| POS
normal  ||| S:202 E:209 ||| JJ
function ||| S:209 E:217 ||| NN
.  ||| S:217 E:219 ||| .
Accordingly ||| S:219 E:230 ||| RB
,  ||| S:230 E:232 ||| ,
a  ||| S:232 E:234 ||| DT
compromise  ||| S:234 E:245 ||| NN
in  ||| S:245 E:248 ||| IN
the  ||| S:248 E:252 ||| DT
blood-brain  ||| S:252 E:264 ||| JJ
barrier  ||| S:264 E:272 ||| NN
( ||| S:272 E:273 ||| -LRB-
BBB ||| S:273 E:276 ||| NNP
)  ||| S:276 E:278 ||| -RRB-
function  ||| S:278 E:287 ||| NN
accompanies  ||| S:287 E:299 ||| VBZ
many  ||| S:299 E:304 ||| JJ
neurologic  ||| S:304 E:315 ||| JJ
disorders ||| S:315 E:324 ||| NNS
,  ||| S:324 E:326 ||| ,
and  ||| S:326 E:330 ||| CC
is  ||| S:330 E:333 ||| VBZ
tightly  ||| S:333 E:341 ||| RB
associated  ||| S:341 E:352 ||| VBN
with  ||| S:352 E:357 ||| IN
brain  ||| S:357 E:363 ||| NN
inflammatory  ||| S:363 E:376 ||| NN
processes  ||| S:376 E:386 ||| VBZ
initiated  ||| S:386 E:396 ||| VBN
by  ||| S:396 E:399 ||| IN
both  ||| S:399 E:404 ||| DT
infiltrating  ||| S:404 E:417 ||| JJ
leukocytes  ||| S:417 E:428 ||| NN
from  ||| S:428 E:433 ||| IN
the  ||| S:433 E:437 ||| DT
blood ||| S:437 E:442 ||| NN
,  ||| S:442 E:444 ||| ,
and  ||| S:444 E:448 ||| CC
activation  ||| S:448 E:459 ||| NN
of  ||| S:459 E:462 ||| IN
glial  ||| S:462 E:468 ||| JJ
cells ||| S:468 E:473 ||| NNS
.  ||| S:473 E:475 ||| .
Those  ||| S:475 E:481 ||| DT
inflammatory  ||| S:481 E:494 ||| JJ
processes  ||| S:494 E:504 ||| NNS
contribute  ||| S:504 E:515 ||| VBP
to  ||| S:515 E:518 ||| TO
determining  ||| S:518 E:530 ||| VBG
the  ||| S:530 E:534 ||| DT
severity  ||| S:534 E:543 ||| NN
and  ||| S:543 E:547 ||| CC
prognosis  ||| S:547 E:557 ||| NN
of  ||| S:557 E:560 ||| IN
numerous  ||| S:560 E:569 ||| JJ
neurologic  ||| S:569 E:580 ||| JJ
disorders ||| S:580 E:589 ||| NNS
,  ||| S:589 E:591 ||| ,
and  ||| S:591 E:595 ||| CC
can  ||| S:595 E:599 ||| MD
both  ||| S:599 E:604 ||| DT
cause ||| S:604 E:609 ||| NN
,  ||| S:609 E:611 ||| ,
and  ||| S:611 E:615 ||| CC
result  ||| S:615 E:622 ||| NN
from  ||| S:622 E:627 ||| IN
BBB  ||| S:627 E:631 ||| NNP
dysfunction ||| S:631 E:642 ||| NN
.  ||| S:642 E:644 ||| .
In  ||| S:644 E:647 ||| IN
this  ||| S:647 E:652 ||| DT
review  ||| S:652 E:659 ||| NN
we  ||| S:659 E:662 ||| PRP
examine  ||| S:662 E:670 ||| VBP
the  ||| S:670 E:674 ||| DT
role  ||| S:674 E:679 ||| NN
of  ||| S:679 E:682 ||| IN
BBB  ||| S:682 E:686 ||| NNP
and  ||| S:686 E:690 ||| CC
inflammatory  ||| S:690 E:703 ||| JJ
responses ||| S:703 E:712 ||| NNS
,  ||| S:712 E:714 ||| ,
in  ||| S:714 E:717 ||| IN
particular  ||| S:717 E:728 ||| JJ
activation  ||| S:728 E:739 ||| NN
of  ||| S:739 E:742 ||| IN
transforming  ||| S:742 E:755 ||| VBG
grown  ||| S:755 E:761 ||| VBN
factor  ||| S:761 E:768 ||| NN
β  ||| S:768 E:770 ||| NNS
( ||| S:770 E:771 ||| -LRB-
TGFβ ||| S:771 E:775 ||| NNP
)  ||| S:775 E:777 ||| -RRB-
signaling ||| S:777 E:786 ||| NN
,  ||| S:786 E:788 ||| ,
in  ||| S:788 E:791 ||| IN
epilepsy ||| S:791 E:799 ||| NN
,  ||| S:799 E:801 ||| ,
stroke ||| S:801 E:807 ||| NN
,  ||| S:807 E:809 ||| ,
and  ||| S:809 E:813 ||| CC
Parkinson ||| S:813 E:822 ||| NNP
's  ||| S:822 E:825 ||| POS
disease ||| S:825 E:832 ||| NN
.  ||| S:832 E:834 ||| .
